Although improved metabolic control of maternal diabetes has reduced the rate of complications during pregnancy, the incidence of congenital malformations is still increased in children of insulin-dependent-diabetic (IDDM) mothers [1±4]. The mechanisms by which maternal diabetes disrupts embryonic development are not completely understood, but the risk of fetal malformation is strongly correlated to the maternal glucose concentration [2±4]. Maternal levels of triglycerides, b-hydroxybutyrate and branched chain amino acids are also of importance for the occurrence of fetal dysmorphogenesis [5] . In the embryo, disturbed metabolism of sorbitol, inositol, arachidonic acid and prostaglandins has been demonstrated in experimental diabetic pregnancy and Diabetologia (1997 Vitamin C supplementation of the maternal diet reduces the rate of malformation in the offspring of diabetic rats
Summary An excess of reactive oxygen species (ROS) has been associated with the increased rate of congenital malformations in experimental diabetic pregnancy. Previous in vitro and in vivo studies show that antioxidants can protect the embryonic development in a diabetic environment. In the present investigation we examined the antiteratogenic capacity of vitamin C, an antioxidative agent not previously evaluated as a dietary supplement in diabetic pregnancy. Normal and streptozotocin diabetic rats were either fed a standard diet or a diet enriched with 0.9, 1.8 or 4 % sodium ascorbate throughout pregnancy. On gestational day 20, the litters of normal and diabetic rats without vitamin C supplement contained 9 and 12 % early resorptions, 2 and 17 % late resorptions and 1 and 27 % malformations, respectively. Vitamin C treatment reduced the rates of late resorptions and malformations in the diabetic groups in proportion to the dose administered. Thus, in the diabetic group with 4 % ascorbate treatment we found unchanged numbers of early resorptions, but only 7 % late resorptions (p < 0.05 vs untreated diabetic pregnancy) and 8 % malformations (p < 0.05 vs untreated diabetic pregnancy). Maternal diabetes did not alter tissue levels of ascorbic acid in the fetuses at term, whereas vitamin C treatment caused accumulation of ascorbic acid in the placenta, maternal and fetal liver. Vitamin C supplementation yielded increased a-tocopherol concentration in the placenta and caused a reduction of the high concentrations of thiobarbituric acid reactive substances (TBARS) in serum of pregnant diabetic rats. Vitamin C treatment reduces the rates of congenital malformations and late resorptions, thereby supporting that ROS are involved in the embryonic dysmorphogenesis of diabetic pregshould have teratologic significance [6] . In addition, excess embryonic reactive oxygen species (ROS) has been implicated in the aetiology of diabetes-induced congenital malformations [6] .
In diabetic pregnancy, experimental studies have indicated increased production of ROS [7, 8] and reduced concentrations of a-tocopherol [9] in embryonic tissues. We and others have shown that the disturbed development of embryos in a diabetic milieu can be normalised by treatment with different antioxidants both in vitro and in vivo [7, 9±19] . These compounds include N-acetylcysteine, reduced glutathione (GSH) ester, superoxide dismutase, catalase, glutathione peroxidase, butylated hydroxytoluene, lipoic acid and vitamin E ± a variety of substances with essentially only antioxidative capacity in common. Notably, ascorbate (vitamin C) has not been previously studied in this context.
Ascorbic acid concentrations in tissues and plasma are reported to be decreased in both animals and humans with diabetes [20±23]. Vitamin C acts as an antioxidant to protect cellular components from ROS induced damage [24, 25] . In addition, ascorbic acid plays an important role in many biochemical processes, such as collagen synthesis [26] , cholesterol synthesis [27, 28] and iron absorption [29] . Ascorbic acid is synthesized from D-glucose in most species, with the exception of primates and guinea pigs [30] . Transport of vitamin C through biological membranes is facilitated by glucose transporters, especially GLUT1 [31±33], and hence, hyperglycaemia has been shown to reduce placental transport of ascorbic acid to the fetus [34, 35] . Ascorbic acid is a water soluble antioxidant, and has the potential to scavenge the superoxide and hydroperoxyl radicals, which are physiological ROS [36] . In addition, ascorbic acid may function as a chain-breaking antioxidant in the lipid phase by an interaction with lipid soluble antioxidants such as vitamin E and coenzyme Q [36, 37] . Ascorbate is the primary antioxidant to be consumed in plasma exposed to oxidative stress [38, 39] , and ascorbate is regarded as the most important scavenger of oxygen radicals in the aqueous phase [25] . However, in the presence of transition metals, ascorbate auto-oxidizes in vitro, and superoxide formation occurs [40] . The significance of the prooxidant activity in vivo is unclear [41] , mainly due to low concentrations of free metal ions under physiological conditions [42] and high concentrations of urate in plasma which inhibits ascorbate auto-oxidation [43] .
By testing the hypothesis that ROS excess is involved in the aetiology of diabetes-induced dysmorphogenesis, we investigated whether supplementation of the maternal diet with ascorbate may restore or normalize the disturbed embryonic development in diabetic pregnancy. Ascorbate has been used previously in the treatment of several diabetic complications [44±47], but has not yet been evaluated in the field of diabetic embryopathy.
Materials and methods

Animals.
A local malformation-prone strain of Sprague-Dawley rats was used in the experiments [48] . The rats were subjected to a 12/12 h light/dark cycle and had free access to tap water and laboratory chow (see below). Some of the virgin female rats were made manifestly diabetic (MD) by a single intravenous injection of streptozotocin (STZ 40 mg/kg, a gift from Pharmacia & Upjohn, Kalamazoo, Mich., USA) 1± 2 weeks before mating with non-diabetic males of the same strain. Untreated virgin females served as normal, non-diabetic controls (N). Manifest diabetes was defined as a serum glucose concentration exceeding 20 mmol/l (Glucose Analyser 2; Beckman Instruments Inc., Fullerton, Calif., USA) 1 week after the STZ injection. All experimental procedures involving animals were approved by the animal ethics committee of the Medical Faculty of Uppsala University.
Treatment with vitamin C. The rats were given powdered rat chow supplemented with sodium ascorbate (Merck, Darmstadt, Germany) at the concentrations 0.9, 1.8 or 4 % (wt/wt, cf. Fig. 1 ). The food was prepared by blending ascorbate into ground rat chow (R36; Lactamin AB, Stockholm, Sweden).
Induction and course of pregnancy. One week after the STZ injection the rats were mated overnight and the morning that sperm were found in the vaginal smear was designated gestational day 0. On gestational day 20 the pregnant rats were anaesthetised with ether and then blood was collected from the abdominal aorta (Fig. 1) . Serum was prepared by centrifugation and immediately frozen in liquid nitrogen. The maternal livers were dissected, weighed, and stored at − 135°C after rapid freezing in liquid nitrogen. The uterine horns were cut open and carefully inspected to reveal all implantations, both viable and non-viable, regardless of size. Viable fetuses and their placentae were weighed and the fetuses were examined for gross malformations, as previously outlined [49] . Briefly, viable fetuses were denoted malformed when they showed facial abnormalities (mainly micrognathia), absence of tail, omphalocele, cranial anomalies, or other gross malformation. Inspection of the resorbed sites yielded a cut-off diameter of 4 mm, which divided the resorptions into those with no identifiable fetal tissues (diameter < 4 mm, essentially only a lump of non-maternal tissue, these were denoted ªearly resorptionsº), and those with one or more identifiable tissues (diameter > 4 mm, placenta and often embryo-fetus identifiable, denoted ªlate resorptionsº). The fetal liver, brain and heart were randomly collected from four viable fetuses in each litter. If malformed fetuses were present in a litter, 1±2 of them were used for organ collection.
Chemical analysis. Maternal liver, placenta and fetal tissues of N, NC 4 %, MD and MDC 4 % groups were homogenized in double distilled water at a concentration of 200 g/l. These homogenates and maternal serum were used for determination of lipid peroxidation (thiobarbituric acid reactive substances, TBARS), ascorbic acid and a-tocopherol. The chemicals used in the study were purchased from Merck.
Analysis of ascorbic acid. Quantification of ascorbic acid was performed according to Jagota and Dani [50] . Initially 200 ml of serum, tissue homogenate or standard preparations of ascorbic acid was precipitated with 800 ml trichloroacetic acid on ice for 5 min and centrifuged at 3000 rev/min. Thereafter, 500 ml of the supernatant was diluted to 2 ml with double distilled water, and 200 ml of Folin-Ciocalteus reagent, diluted in double distilled water (1 : 9), was added. After 10 min the absorbance of the samples was measured at 760 nm with a Beckman DU-65 Spectrophotometer (Beckman Instruments Inc.).
Analysis of a-tocopherol. To estimate the content of a -tocopherol, 500 ml of the tissue homogenate or serum in water was initially diluted with an aliquot of 500 ml methanol. The sample was manually shaken for 3 min with 2 ml of hexane in a Teflon capped glass tube and then centrifuged. For fetal samples, the hexane phase was concentrated 10 times by drying under a stream of nitrogen and dilution in 200 ml of hexane. Subsequently, 100 ml of the hexane phase was analysed by normal phase HPLC by injection into a 5 mm Spherisorb amino column (4.6 × 250 mm, Phase Separation Ltd, Deeside, UK) at a flow rate of 1 ml/min. The eluent was isocratic isooctane/tertbutyl-methyl-ether/methanol (75/25/0.5). The effluent was monitored with a Shimadzu RF-10 A Fluorometer (Shimadzu Corporation, Kyoto, Japan) at excitation wavelength 295 nm and emission wavelength 327 nm. a -Tocopherol eluted at approximately 4.5 min.
Analysis of TBARS. TBARS was determined by a modified version of the method described by Mihara et al. [51] . Initially, 200 ml of the tissue homogenate or serum was boiled with 750 ml phosphoric acid (0.19 mol/l), 250 ml thiobarbituric acid (42 mmol/l) and 300 ml double distilled water for 60 min. After boiling the samples were precipitated with an aliquot of methanol/NaOH (91/9, 1 mol/l NaOH) and centrifuged for 5 min. The supernatant was measured fluorometrically at excitation wavelength 532 nm and emission wavelength 553 nm (Perkin Elmer LS 5B luminescence spectrophotometer; Perkin Elmer Ltd, Beaconsfield, Buckinghamshire, UK). Standards were prepared from malonyldialdehydbis(dietylacetal) and were treated identically as the tissue homogenates.
Statistical analysis. Mean ± SEM for the treatment groups was calculated from litter means. Significant differences between and within groups were estimated from litter means by analysis of variance (ANOVA) with the applied test of Fishers Protected Least Significant Difference ad modum Winer [52] , or the Mann-Whitney U-test [53] . Significance levels are given in each table legend. A numerical difference between means which yielded a p -value in the range of 0.05 to 0.1 was denoted ªtendencyº in the text. The statistical analyses were performed using the program StatView (version 4.02) for Macintosh.
Results
Maternal status. On the day of conception, the mean weight of the rats in the diabetic groups tended to be smaller than the mean weight of those in the normal groups (Table 1) . During pregnancy the diabetic groups gained less weight than the normal groups, regardless of diet. The ascorbate addition to the diet did not appear to have any negative effects on animal health, food consumption, or weight gain. The liver weight was increased in the diabetic groups compared to the normal groups. Again, this was not affected by ascorbate treatment. The serum glucose concentration of the STZ-diabetic rats was elevated about six times compared to that of the normal rats. Ascorbate treatment did not exert any consistent effect on serum glucose concentrations ( Table 1) .
Outcome of pregnancy. The mean number of implantations per litter were similar in all groups regardless of diabetes and ascorbate treatment ( Table 2 ). The total numbers of resorptions were increased in all the diabetic groups, and no consistent effect of ascorbate treatment could be identified (Table 2) . Comparing early and late resorptions, however, revealed that the early resorption rate was similar in the normal and diabetic groups, whereas the rate of late resorptions was increased in the MD group (Table 3) . Ascorbate treatment did not affect early resorptions but decreased the frequency of late resorptions in the diabetic groups (Table 3 ). The malformation rate was increased in the diabetic groups compared to the normal groups, as expected, but was decreased Table 1 . Maternal body weight on gestational day 0, day 20 and the weight gain during pregnancy, maternal liver weight and serum glucose by the interruption of pregnancy at gestational day 20 by ascorbate treatment. The decrease of the malformation rate was proportional to the increase in ascorbate dose in the diet. Micrognathia accounted for 79 % of all malformations, although it was never found in any of the normal groups, as previously observed [48] . Cranial skeletal anomalies (micrognathia, exencephaly, short nose, distorted mid face with protruding forehead) accounted for 87 % of the malformations, whereas absence of tail (11 %), and omphalocele (2 %) were much less common. Ascorbate treatment prevented micrognathia in a dose-dependent manner (data not shown), whereas the other anomalies were too few to allow a statistical analysis. Altogether, the data show that ascorbate treatment decreases the rates of malformations and late resorptions, but not early resorptions (Fig. 2 ).
Fetal and placental weights. Fetuses from diabetic groups were found to be smaller than fetuses from normal groups (Table 4 ). Vitamin C treatment did not affect fetal weight. The placental weight tended to be increased in diabetic groups compared to normal groups. Vitamin C treatment did not affect placental weight in the normal groups, but 4 % vitamin C supplementation tended to reduce the increase of placental weight in the diabetic group (Table 4) .
Organ weights. The fetal organ weight per body weight did not differ between morphologically normal and malformed fetuses, therefore, the data were combined ( Table 5 ). The relative weight of fetal liver did not differ between the N and MD groups, whereas the fetal brain was slightly smaller in the MD group compared to the N group. Vitamin C treatment tended to increase these organ weights in the MDC group. In marked contrast, the relative weight of the fetal heart was increased in the diabetic groups compared to the normal groups and vitamin C treatment did not normalize this difference (Table 5) . Normal and diabetic rats with standard diet (N and MD) or with 0.9 % (MDC 0.9 %), 1.8 % (NC 1.8 % and MDC 1.8 %) or 4 % (NC 4 % and MDC 4 %) ascorbate added to the diet. Data are presented as mean ± SEM. n = number of observations Statistical analysis with ANOVA: b p < 0.01 vs N; c p < 0.001 vs N Biochemical analysis. We were unable to detect any biochemical difference with regard to concentration of vitamin C, vitamin E, or TBARS between malformed and non-malformed fetuses within each group, which allowed the data on the fetal outcome to be combined without regard to morphology of the fetus. The biochemical estimation in tissues of untreated rats (N and MD groups) and their offspring revealed the lowest ascorbic acid concentrations in placenta and the highest in fetal brain (Table 6 ). Maternal and fetal liver had similar ascorbic acid concentration. For a-tocopherol, the order of tissue concentration was: maternal liver > placenta > fetal brain > fetal liver, which is opposite that of TBARS in the same tissues (Table 6 ). Compared to maternal liver, maternal serum had low concentration of ascorbic acid and a -tocopherol, but similar concentration of TBARS (Table 6 ). In maternal serum, diabetes did not affect ascorbic acid concentration, but increased a -tocopherol levels and tended to increase TBARS concentration. Ascorbate treatment of the diabetic rats yielded increased ascorbic acid concentration and decreased TBARS levels in serum (Table 6 ). In maternal liver, diabetes did not affect any of the measured substances, whereas ascorbate treatment increased ascorbic acid and reduced TBARS concentrations in the MDC 4 % group (Table 6 ). In the placenta, diabetes did not alter the levels of any of the estimated compounds. In both NC 4 % and MDC 4 % groups ascorbate treatment increased ascorbic acid and atocopherol levels in the placenta of the diabetic rats (tendency for a-tocopherol in NC 4 %), but did not affect TBARS concentration (Table 6 ). In fetal brain, maternal diabetes increased a -tocopherol and TBARS levels, whereas ascorbate treatment of the mother did not change any of the studied parameters, Table 6 . Estimation of contents of vitamin C, vitamin E, and TBARS in maternal serum, maternal liver, placenta, fetal brain, fetal liver (Table 6 ). In fetal liver we found extremely low a -tocopherol levels (less than 1 % of the concentration in maternal liver). No change in ascorbic acid or a-tocopherol levels was caused by diabetes, but a pronounced increase in TBARS concentration was detected in the MD offspring. Ascorbate treatment increased ascorbic acid concentration, did not affect a -tocopherol concentration, but tended to decrease the elevated TBARS levels in the offspring of diabetic rats (Table 6 ).
Discussion
The current report shows that vitamin C treatment of pregnant streptozotocin diabetic rats has the potential to prevent congenital malformations as well as resorptions occurring in the later part of gestation. The rate of malformations in the diabetic group given 4 % ascorbate in the present study (8.1 %) is comparable to the rates we previously demonstrated in diabetic rats supplemented with 2 % vitamin E (5.5 % malformations) or 1 % BHT (2.3 % malformations) [9, 14] . The doses of vitamin E and BHT are of similar molar concentration, whereas the ascorbate molar dose is approximately four times that of vitamin E and BHT. Thus, it appears that the water soluble antioxidant requires higher doses in order to have a similar effect as the previously tested lipid soluble antioxidants. Assuming that these three antioxidants have the same antioxidative capacity per molecule, the results may suggest that the oxidative process damaging the embryogenesis is mainly confined to the lipid compartment of the cell.
The ascorbate treatment diminished the malformation rate, but also decreased the occurrence of larger resorptions. The latter represents implanted conceptii which died in the later part of pregnancy, presumably due to severe lethal malformations. This notion is supported by findings of malformations in early pregnancy but only resorptions at term in offspring exposed to excess mannose in utero [54] . Assuming that a large proportion of these are due to disturbances in the development of the heart ± which is suggested by the persistent cardiac hypertrophy in fetuses of diabetic rats found in this and other studies [9, 55, 56] , as well as by the increased cardiac malformation rate in human diabetic pregnancy [57] ± we can suggest a unifying concept for the diabetic dysmorphogenesis by identifying the neural crest cell population as a specific vulnerable cell population. A large proportion of the diabetes-induced viable malformations in this study are likely to be of neural crest origin (micrognathia, and some other facial anomalies), and the late resorptions may represent other, more severe, neural crest cell defects, leading to hampered development of the great vessels and the fetal heart [58] . The effect of the anti-teratogenic treatment would be to block oxidative damage in this cell population. Indeed, this notion is supported by earlier results in vitro, where antioxidant treatment (N-acetylcysteine) diminished the disrupting effect of high glucose on embryonic neural crest cell development [59] .
On the other hand, the small early resorptions are likely to be the result of other aetiologic processes than the late resorptions, since they are only marginally increased in frequency, if at all, by the maternal diabetic state, and they remain unaffected by the ascorbate treatment. In this study, the small resorptions seem to represent a strain-related defect in early embryonic development [60] .
The measurement of maternal and fetal anti-oxidative status at term rather than during organogenesis when the dysmorphogenesis is likely to be induced [56, 61, 62] was dictated by the necessity to recognize the malformations, which in the majority of cases is possible only towards the end of gestation. This applies to micrognathia and other gross malformations. Also, we were interested in studying the effects of the ascorbate treatment, and to find out if a putative imbalance of fetal and maternal antioxidative parameters during early pregnancy would have a discernible correlation in the late gestation. Finding such a fetal or maternal parameter (e. g. in maternal serum) could be of clinical importance, since a large proportion of human malformations present themselves for the first time at birth or in late pregnancy, when there is no possibility of acquiring a sample from the organogenetic period.
The biochemical changes estimated in the different maternal and fetal compartments/organs displayed marked variations, both with regard to diabetes and ascorbate treatment. Thus, the maternal diabetic state did not cause decrease of ascorbate levels, as has been described by other authors [20±23] . Another, somewhat paradoxical, effect of the diabetic state was the slight increase in a -tocopherol concentration in maternal serum and fetal brain tissue. These results have been encountered previously in studies of vitamin E administration to pregnant diabetic rats [9, 15] , and should be related to the high lipid concentration of the maternal diabetic serum, as well as in the fetal brain [63] , thereby allowing a large amount of a -tocopherol to be dissolved in the particular compartments. A compensatory reaction to a diabetes-induced state of oxidative stress, as revealed by the increased TBARS levels in maternal serum and fetal tissue, may also have contributed to the accumulation of a -tocopherol in maternal serum and fetal brain.
If the measurements of a -tocopherol did not always display an expected pattern, the effect of ascorbate treatment was more predictable. Thus, in almost all tissues we found increased ascorbate levels after administration of the antioxidant to the mother, irrespective if she was diabetic or not. In the placenta, there was evidence of an interaction between the antioxidants, since the ascorbate-treated animals showed increased a -tocopherol concentration. Lastly, the TBARS concentration was decreased in maternal serum, and tended to be in fetal liver, by ascorbate administration. The results support the notion that ascorbate is readily transported to the conceptus, taken up by the embryonic and fetal tissues, and thereby exerts an antioxidative (and developmentally beneficial) effect in the offspring.
It is evident that diabetes can cause ROS-induced damage in embryonic and fetal tissue [9, 64] , and that antioxidants can prevent this damage [9] . The presence of excess radicals has been indicated in vitro in embryonic tissue exposed to high glucose concentrations [7, 8] . The suggested source for the ROS has been the embryonic mitochondria [8, 65] , and the effect of the antioxidative agents would be to block the oxidative damage caused. Recently, however, another compound, the reactive oxo-aldehyde 3-deoxyglucosone (3-DG), a strong glycating agent [66] , was implicated as a bridging teratogen in hyperglycemia-induced dysmorphogenesis in vitro [67] . This compound is much more reactive than glucose, and able to modify proteins to form AGE-like compounds, which may have profound effects on embryogenesis, unless enough compensatory forces, such as sufficient antioxidative capacity, are present in the embryo. Since the teratogenic effect of 3-DG can be diminished by antioxidants in vitro [67] , it is possible that vitamin C may have exerted some of its effects by counteracting the glycating action of 3-DG, an issue which is currently under investigation.
We found no signs of toxicity with the doses used in the present study, thereby providing support for the feasibility of an anti-teratogenic antioxidant therapy in diabetic pregnancy. If antioxidative treatment with ascorbate will become a clinical entity in the future, the potential prooxidative activity of vitamin C has to be considered carefully. In the presence of free metals, ascorbic acid can induce radical damage, both in vitro [40] and in vivo in patients with idiopathic haemochromatosis and iron overload [41] . Since free metals are essential for the prooxidative effect, the question arises whether there are sufficient amounts of unbound metals in diabetic individuals to induce autooxidation of ascorbic acid. Glycation of proteins occurs in diabetes, and the binding capacity of transferrin to iron is reduced when this transport protein is glycated [68] . On the other hand, the relevance of glycation in vivo has been questioned [69] . To our knowledge, there are at present no reports showing a prooxidative effect of ascorbic acid in vivo in diabetes (without haemochromatosis). Due to the potential use of ascorbic acid in future prophylactic therapies, these questions need to be further addressed.
In conclusion, we have shown that vitamin C supplementation to the diet exerts antioxidative effects in pregnant diabetic rats and restores fetal development, i. e. decreases the occurrence of late resorptions and malformations in the litters. Furthermore, the data support that the mechanisms causing early and late resorptions are different. Excess ROS apparently contribute to the aetiology of diabetic complications in pregnancy, and this finding may indicate a direction for future preventive treatments.
